Pramiracetam: A nootropic agent with improved efficacy in patients with senile or presenile cognitive impairment

G. Nappi, X. Rabasseda, N. Mealy

Research output: Contribution to journalArticle

  • 5 Citations

Abstract

As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.

LanguageEnglish
Pages469-482
Number of pages14
JournalDrugs of Today
Volume30
Issue number6
StatePublished - 1994

Fingerprint

Nootropic Agents
Learning
Brain Diseases
Vascular Diseases
Pharmaceutical Preparations
Dementia
Alzheimer Disease
Animal Models
Pharmacokinetics
Safety
Cognitive Dysfunction
pramiracetam
Population

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Pramiracetam : A nootropic agent with improved efficacy in patients with senile or presenile cognitive impairment. / Nappi, G.; Rabasseda, X.; Mealy, N.

In: Drugs of Today, Vol. 30, No. 6, 1994, p. 469-482.

Research output: Contribution to journalArticle

@article{2dbfa6de6acf402b82a554dce3da08e0,
title = "Pramiracetam: A nootropic agent with improved efficacy in patients with senile or presenile cognitive impairment",
abstract = "As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.",
author = "G. Nappi and X. Rabasseda and N. Mealy",
year = "1994",
language = "English",
volume = "30",
pages = "469--482",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - Pramiracetam

T2 - Drugs of Today

AU - Nappi,G.

AU - Rabasseda,X.

AU - Mealy,N.

PY - 1994

Y1 - 1994

N2 - As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.

AB - As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.

UR - http://www.scopus.com/inward/record.url?scp=0027970641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027970641&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 469

EP - 482

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 6

ER -